CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

What Does the Genetic Testing Landscape Look Like?

What Does the Genetic Testing...

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Scopus BioPharma Makes New Management Appointment Following the Acquisition of Chief Immunotherapy Firm

Scopus BioPharma Makes New Management...

The Impact of AI and ML in Genomics

The Impact of AI and ML in Genomics

Lykan Bioscience Collaborates with Vineti to Take Cell-Based Therapies from the Clinic to the Market

Lykan Bioscience Collaborates with...

Singapore to grow into a global hub of biotechnology

Singapore to grow into a global hub...

US FDA Award VICO with Therapeutics Orphan-Drug Designation for VO659

US FDA Award VICO with Therapeutics...

An Insight into What Genome is

An Insight into What Genome is

What Does the Genetic Testing Landscape Look Like?

What Does the Genetic Testing...

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Scopus BioPharma Makes New Management Appointment Following the Acquisition of Chief Immunotherapy Firm

Scopus BioPharma Makes New Management...

The Impact of AI and ML in Genomics

The Impact of AI and ML in Genomics

Lykan Bioscience Collaborates with Vineti to Take Cell-Based Therapies from the Clinic to the Market

Lykan Bioscience Collaborates with...

Singapore to grow into a global hub of biotechnology

Singapore to grow into a global hub...

US FDA Award VICO with Therapeutics Orphan-Drug Designation for VO659

US FDA Award VICO with Therapeutics...

An Insight into What Genome is

An Insight into What Genome is

Quantum Genomics Raises €3 Million in Non-dilutive Financing

Life Sciences Review Life Sciences Review | Wednesday, August 18, 2021
Tweet

The latest funding secured by Quantum Genomics will enable the acceleration of R&D programs.


FREMONT, CA: Quantum Genomics, a biopharmaceutical firm specializing in the development of a new class of drugs that directly targets the brain to treat difficult-to-treat/resistant hypertension and heart failure, today announces it has secured ‚ €3 million in non-dilutive financing through grants from the French government and BNP bank and an R&D loan from Bpifrance.


BNP bank has given a ‚ €1.5 million loan, guaranteed by the French government (PGE) with an initial 12 months maturity, at a rate of 0.25 percent. The firm has been offered the option to request five years amortization. Bpifrance has granted a ‚ €1.5 million innovation and R&D loan for 7.6 years at an interest rate of 0.72 percent. The first reimbursement is scheduled for December 31, 2023.


 


The Company would like to thank the French government, Bpifrance, and its banking partners for supporting this financing. This additional non-dilutive financing, which processes were initiated last November 2020, secured the treasury in a context that remains uncertain. This comes at an essential time for the Company, following the recent capital raise in December 2020 and the signing of several partnerships with different strategic partners in 2020, all of which will strengthen and boost R&D programs.


Quantum Genomics is a biopharmaceutical firm specializing in developing a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only firm in the world exploring this innovative method that directly targets the brain.


Weekly Brief

loading
Top 10 Genomics Solution Companies in Europe - 2021
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/quantum-genomics-raises-3-million-in-nondilutive-financing-nwid-368.html